Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent or assent form~* Male/female, 9 to 45 years of age, inclusive~* Body weight between 33 and 136 kg, inclusive~* Facial acne vulgaris with:~* 20-50 inflammatory lesions (papules, pustules and nodules) 30-100 noninflammatory lesions (open and closed comedones)~* No more than 2 nodules~* IGA score of moderate (3) or severe (4)~* Negative urine pregnancy test at baseline - females of childbearing potential~* Agrees to use an effective method of contraception throughout the study~* Refrain from use of any other acne medications and medicated cleansers, and avoid excessive sun exposure and tanning booths for duration of study~* Able to fulfill the requirements of protocol, indicated willingness to participate in the study and agrees to all study procedures (including mandatory photography) by providing written informed consent/assent and an authorization to disclose protected health information (PHI)~Exclusion Criteria:~* Has a dermatological condition of the face that could interfere with the clinical evaluations~* Has a history of any of the following:~* Allergy to tetracycline-class antibiotics or to any ingredient in the study drug~* Pseudomembranous colitis or antibiotic associated colitis~* Treated for any type of cancer within the last 6 months~* Has known resistance to other tetracyclines~* Has received any of the following treatments within 12 weeks of screening:~* Systemic retinoids~* Systemic corticosteroids~* Androgens/anti-androgenic therapy (eg, anabolic steroids, spironolactone)~* Non-medicated procedures for the treatment of acne (eg, laser, light or ThermaClear)~* Has used any acne affecting treatment without an appropriate washout period~* Has initiated hormonal contraceptive use within 12 weeks prior to screening or plans to initiate or switch hormonal contraceptive products during the study period~* Is pregnant, lactating or planning a pregnancy during the study period~* Has any other disorder causing hyperandrogenism including, but not limited to polycystic ovary syndrome, adrenal or ovarian tumors, Cushings disease or congenital adrenal hyperplasia~* Has drug-induced acne~* Has significant intercurrent illness, psychiatric disposition or other factors that, in the opinion of the Investigator or Medical Monitor, precludes participation in the study~* Is currently participating, or has participated within 30 days prior to the screening period in an investigational drug or device study~* Has previously participated in any clinical trial involving the use of sarecycline~* Is judged by the Investigator to be unsuitable for any reason

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Sarecycline (Type: EXPERIMENTAL): Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete